Clinical Report: SALWEEN Results Show Durable PCV Treatment
Overview
The SALWEEN study demonstrated that more than half of Asian patients with polypoidal choroidal vasculopathy (PCV) required fewer injections after one year of treatment with Vabysmo. Patients experienced an average gain of nearly 9 letters in visual acuity, indicating significant therapeutic benefits.
Background
Polypoidal choroidal vasculopathy (PCV) is a major cause of vision loss, particularly in Asian populations, where it accounts for up to 60% of neovascular age-related macular degeneration (nAMD) cases. The SALWEEN study's findings are crucial as they suggest that Vabysmo may reduce the treatment burden associated with frequent injections, which is a significant concern for patients and healthcare providers alike. With the aging population in Asia projected to increase AMD cases, effective long-term treatment options are essential.
Data Highlights
| Outcome | Results |
|---|---|
| Average BCVA Gain | 8.9 letters |
| Patients Needing Fewer Injections | Over 50% |
| Complete Regression of Lesions | 61% |
| Lesion Inactivation | 86% |
Key Findings
- Patients treated with Vabysmo gained an average of 8.9 letters in best-corrected visual acuity (BCVA) after one year.
- More than 50% of patients were able to extend treatment intervals to every 20 weeks.
- 61% of patients showed complete regression of polypoidal lesions.
- 86% of patients achieved lesion inactivation, reducing the risk of bleeding and vision loss.
- Safety results were consistent with previous global trials of Vabysmo.
Clinical Implications
The findings from the SALWEEN study suggest that Vabysmo may offer a durable treatment option for PCV, potentially reducing the frequency of injections needed by patients. This could lead to improved patient adherence and satisfaction, as well as better management of the disease in the context of an aging population.
Conclusion
The SALWEEN study highlights the potential of Vabysmo as an effective long-term treatment for PCV, with significant improvements in visual acuity and reduced treatment burden. Ongoing research will further elucidate its efficacy and safety beyond one year.
References
- Ophthalmology Management, 2025 -- SALWEEN Results Presented at Euretina Show Durable PCV Treatment
- Retinal Physician, 2025 -- 16-Week Data From SALWEEN Fill the Gap for Patients With PCV
- Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS)
- Retinal Physician, 2025 -- SALWEEN Results Show Durable PCV Treatment
- Blood Cancer Journal — Efficacy of Brentuximab Vedotin Combined with Chemotherapy in First-Line Treatment of Systemic Anaplastic Large Cell Lymphoma: A 5-Year Subgroup Analysis from the ECHELON-2 Trial
- Infection — Sustained Effectiveness of a Patient-Centered Approach for Individuals with Asplenia: A Three-Year Analysis of the PrePPS Study
- Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS) | Request PDF
- SALWEEN Results Show Durable PCV Treatment | Retinal Physician
- https://bmcophthalmol.biomedcentral.com/counter/pdf/10.1186/s12886-025-04249-8.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.